The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma.
Spahn S, Kleinhenz F, Shevchenko E, Stahl A, Rasen Y, Geisler C, Ruhm K, Klaumuenzer M, Kronenberger T, Laufer SA, Sundberg-Malek H, Bui KC, Horger M, Biskup S, Schulze-Osthoff K, Templin M, Malek NP, Poso A, Bitzer M.
Spahn S, et al. Among authors: geisler c.
Nat Commun. 2024 Feb 12;15(1):1287. doi: 10.1038/s41467-024-45247-6.
Nat Commun. 2024.
PMID: 38346946
Free PMC article.